Publications

• NCCN Practice Guidelines for acute myelogenous leukemia
  O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Carabasi, M. H., Coutre, S. E., Erba, H. P., … Tallman, M. S. (2000). NCCN Practice Guidelines for acute myelogenous leukemia. ONCOLOGY-NEW YORK, 14(11A), 53–61.
• United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
  Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., … Warrell, R. P. (2001). United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. JOURNAL OF CLINICAL ONCOLOGY, 19(18), 3852–3860.
• Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed
  Keating, M. J., Cazin, B., Coutre, S., Birhiray, R., Kovacsovics, T., Langer, W., … Herait, P. (2002). Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. JOURNAL OF CLINICAL ONCOLOGY, 20(1), 205–213.
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., … Druker, B. J. (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. BLOOD, 99(10), 3530–3539.
  
• Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia Nguyen, D. D., Cao, T. M., Dugan, K., Starcher, S. A., Fechter, R. L., & Coutre, S. E. (2002). Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. CLINICAL LYMPHOMA, 3(2), 105–10.
  
• T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). Cao, T. M., & Coutre, S. E. (2003). T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). Hematology , 8(1), 1–6.
  
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., … Gilliland, D. G. (2003). A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. NEW ENGLAND JOURNAL OF MEDICINE, 348(13), 1201–14.
  
• PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR alpha-induced myeloproliferative disease Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., … Gilliland, D. G. (2003). PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR alpha-induced myeloproliferative disease. CANCER CELL, 3(5), 459–469.
  
• Management of advanced chronic lymphocytic leukemia. Cao, T. M., & Coutre, S. E. (2003). Management of advanced chronic lymphocytic leukemia. Current Hematology Reports, 2(1), 65–72.
  
• Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate Coutre, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. SEMINARS IN CANCER BIOLOGY, 14(1), 23–31.
  
• The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutre, S. E. (2004). The HP1L1-PDIGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. BLOOD, 103(8), 2879–91.
  
• Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., … Hillmen, P. (2004). Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia. CLINICAL LYMPHOMA, 4(4), 220–227.
  
• Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial McCullough, J., Vesole, D. H., Benjamin, R. J., Slichter, S. J., Pineda, A., Snyder, E., … Conlan, M. G. (2004). Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. BLOOD, 104(5), 1534–41.
  
• Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Coutré, S., & Gotlib, J. (2004). Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in Cancer Biology, 14(4), 307–15.
  
• Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., … Coutre, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. BLOOD, 106(8), 2865–70.
  
• The evolving role of alemtuzumab in management of patients with CLL Faderl, S., Coutre, S., Byrd, J. C., Dearden, C., Denes, A., Dyer, M. J. S., … Rai, K. (2005). The evolving role of alemtuzumab in management of patients with CLL. LEUKEMIA, 19(12), 2147–2152.
  
• Acute myeloid leukemia clinical practice guidelines in oncology. O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Byrd, J. C., Coutre, S. E., Damon, L. E., … Tallman, M. S. (2006). Acute myeloid leukemia clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(1), 16–36.
  
• Refractory hematuria from amyloidosis successfully treated by splenectomy Ma, J. F., Coutre, S. E., Curet, M. J., & Brooks, J. D. (2006). Refractory hematuria from amyloidosis successfully treated by splenectomy. UROLOGY, 67(5).
  
• Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Nabhan, C., Coutre, S., & Hillmen, P. (2007). Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? BRITISH JOURNAL OF HAEMATOLOGY, 136(3), 379–392.
  
• Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., … Baccarani, M. (2007). Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. BLOOD, 109(8), 3207–13.
  
• Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801 DeAngelo, D. J., Yu, D., Johnson, J. L., Coutre, S. E., Stone, R. M., Stopeck, A. T., … Larson, R. A. (2007). Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. BLOOD, 109(12), 5136–42.
  
• International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia Rawstron, A. C., Villamor, N., Ritgen, M., Boettcher, S., Ghia, P., Zehnder, J. L., … Hillmen, P. (2007). International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. LEUKEMIA, 21(5), 956–64.
  
• Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval Moayeri, S. E., Coutre, S. E., Ramirez, E. J., & Westphal, L. M. (2007). Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 196(4).
  
• Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., … Coutre, S. (2007). Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. BLOOD, 110(7), 2309–2315.
  
• Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer Hamilton, C. A., Kao, J. M., Coutre, S. E., & Teng, N. N. H. (2007). Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer. GYNECOLOGIC ONCOLOGY, 106(2), 423–26.
  
• Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase Cortes, J., Kim, D.-W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., … Talpaz, M. (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. LEUKEMIA, 22(12), 2176–2183.
  
• Acute myeloid leukemia. O'Donnell, M. R., Appelbaum, F. R., Coutre, S. E., Damon, L. E., Erba, H. P., Foran, J., … White, F. L. (2008). Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network , 6(10), 962–993.
  
• Optimizing therapy for acute myeloid leukemia. Kohrt, H. E., & Coutre, S. E. (2008). Optimizing therapy for acute myeloid leukemia. Journal of the National Comprehensive Cancer Network , 6(10), 1003–16.
  
• Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma Chen, C., Reece, D. E., Siegel, D., Niesvizky, R., Boccia, R. V., Stadtmauer, E. A., … Rajkumar, V. (2009). Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 146(2), 164–70.
  
• Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities Ho, D. Y., Lin, M., Schaenman, J., Rosso, F., Leung, A. N. C., Coutre, S. E., … Montoya, J. G. (2011). Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities. MYCOSES, 54(1), 59–70.
  
• Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma Tong, W.-G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R. D., … Wierda, W. G. (2010). Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma. JOURNAL OF CLINICAL ONCOLOGY, 28(18), 3015–22.
  
• Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710 Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., Stone, R. M., … Larson, R. A. (2010). Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. BLOOD, 116(19), 3751–3757.
  
• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81.
  
• Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia Advani, A. S., Gundacker, H. M., Sala-Torra, O., Radich, J. P., Lai, R., Slovak, M. L., … Appelbaum, F. R. (2010). Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 151(5), 430–434.
  
• Classification and Risk Stratification for Acute Promyelocytic Leukemia Coutre, S. (2010). Classification and Risk Stratification for Acute Promyelocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 10, S127–S129.
  
• CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., … Levy, R. (2011). CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. BLOOD, 117(8), 2423–32.
  
• Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., … Smith, B. D. (2011). Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. BLOOD, 117(12), 3294–3301.
  
• Acute Myeloid Leukemia O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Coutre, S. E., Damon, L. E., … Wang, E. S. (2011). Acute Myeloid Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(3), 280–317.
  
• Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia Wendtner, C.-M., Hillmen, P., Mahadevan, D., Buehler, A., Uharek, L., Coutre, S., … Chanan-Khan, A. A. (2012). Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 53(3), 417–23.
  
• Treatment advances have not improved the early death rate in acute promyelocytic leukemia McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., & Medeiros, B. C. (2012). Treatment advances have not improved the early death rate in acute promyelocytic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 133–36.
  
• Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37.
  
• Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901.
  
• Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., Arber, D. A., & Zehnder, J. L. (2012). Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(1), 45–50.
  
• Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., … Pastan, I. (2012). Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 30(15), 1822–1828.
  
• Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., … Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957–60.
  
• Acute Lymphoblastic Leukemia Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Bellam, N., Blum, W., … Gregory, K. M. (2012). Acute Lymphoblastic Leukemia. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(7), 858–913.
  
• Acute myeloid leukemia. O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., Attar, E., … Gregory, K. M. (2012). Acute myeloid leukemia. Journal of the National Comprehensive Cancer Network , 10(8), 984–1021.
  
• Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study Kantarjian, H., Faderl, S., Garcia-Manero, G., Luger, S., Venugopal, P., Maness, L., … Plunkett, W. (2012). Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. LANCET ONCOLOGY, 13(11), 1096–1104.
  
• High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., Aulitzky, W., … Kantarjian, H. (2013). High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 676–683.
  
• Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96.
  
• Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter? Results From a Prospective Randomized Trial Lamanna, N., Heffner, L. T., Kalaycio, M., Schiller, G., Coutre, S., Moore, J., … Weiss, M. A. (2013). Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter? Results From a Prospective Randomized Trial. CANCER, 119(6), 1186–94.
  
• CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING Gibbs, C. S., Coutre, S. E., Tsiang, M., Li, W. X., Jain, A. K., Dunn, K. E., … Leung, L. L. K. (1995). CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING. NATURE, 378(6555), 413–416.
  
• Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Kipps, T. J., Swinnen, L. J., Wierda, W. G., Jones, J. A., Coutre, S. E., Smith, M. R., … Humerickhouse, R. (2011). Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). BLOOD, 118(21), 1669–1669.
  
• Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study) Wendtner, C., Hillmen, P., Mahadevan, D., Stilgenbauer, S., Uharek, L., Coutre, S., … Chanan-Khan, A. A. (2010). Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). BLOOD, 116(21), 591–92.
  
• Engineering thrombin to function as a selective anticoagulant by identification of a Glu to Lys mutation that converts thrombin into an exclusive protein C activator. Tsiang, M., Li, W. X., Jain, A. K., Mao, C. T., Dunn, K. E., MATSUMURA, S. Y., … Gibbs, C. S. (1995). Engineering thrombin to function as a selective anticoagulant by identification of a Glu to Lys mutation that converts thrombin into an exclusive protein C activator. BLOOD, 86(10), 1779–1779.
  
• Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21).
  
• A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., & Liedtke, M. (2012). A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma. BLOOD, 120(21).
  
• PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation. Gotlib, J., Berube, C., Ruan, J., Growney, J., Dugan, K., Falkow, R., … Coutre, S. (2003). PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation. BLOOD, 102(11), 919A–919A.
  
• Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., … Zehnder, J. L. (2010). Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification. BLOOD, 116(21), 1357–58.
  
• A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML) Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347–47.
  
• Real-time PCR assay for quantitation of BCR-ABL mRNA in patients with chronic phase CML treated with the tyrosine kinase inhibitor GLEEVEC (TM) (STI-571). Gotlib, J., Jones, C. D., Zheng, K. H., Yeung, C., Dugan, K., Fechter, L., … Coutre, S. (2001). Real-time PCR assay for quantitation of BCR-ABL mRNA in patients with chronic phase CML treated with the tyrosine kinase inhibitor GLEEVEC (TM) (STI-571). BLOOD, 98(11), 258B–259B.
  
• Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., & Medeiros, B. C. (2009). Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported. BLOOD, 114(22), 420–21.
  
• THROMBIN APTAMER AS AN ANTICOAGULANT FOR CANINE CARDIOPULMONARY BYPASS Coutre, S. E., Griffin, L. C., Moon, M. R., DeAnda, A., Law, V. S., Leung, L. L. K., & Miller, D. C. (1993). THROMBIN APTAMER AS AN ANTICOAGULANT FOR CANINE CARDIOPULMONARY BYPASS. THROMBOSIS AND HAEMOSTASIS, 69(6), 540–540.
  
• The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study O'Brien, S., Burger, J. A., Blum, K. A., Furman, R. R., Coutre, S. E., Sharman, J., … Byrd, J. C. (2011). The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. BLOOD, 118(21), 449–450.
  
• The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., … O'Brien, S. (2012). The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. BLOOD, 120(21).
  
• A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor in Chronic Lymphocytic Leukemia and Multiple Myeloma. Wierda, W. G., Chen, R., Plunkett, W., Coutre, S., Badros, A. Z., Popplewell, L., … Bolton, M. G. (2008). A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor in Chronic Lymphocytic Leukemia and Multiple Myeloma. BLOOD, 112(11), 1090–90.
  
• Pilot study of I-131-tositumomab in advanced, previously treated, refractory chronic lymphocytic leukemia. Palestro, C. J., Gupta, N. K., Cao, T. M., French, J. N., Goris, M. L., Capizi, R., … Coutre, S. E. (2002). Pilot study of I-131-tositumomab in advanced, previously treated, refractory chronic lymphocytic leukemia. JOURNAL OF NUCLEAR MEDICINE, 43(5), 312P–312P.
  
• Pilot study of Bexxar in advanced previously heavily treated refractory chronic lymphocytic leukemia (CLL). Gupta, N. K., Cao, T. M., French, J. N., Goris, M. L., Capizi, R., Califano, J., … Coutre, S. E. (2001). Pilot study of Bexxar in advanced previously heavily treated refractory chronic lymphocytic leukemia (CLL). BLOOD, 98(11), 290B–290B.
  
• Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL). Cao, T. M., Nguyen, D. D., Dugan, K., Starcher, S. A., Fechter, R. L., & Coutre, S. E. (2001). Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL). BLOOD, 98(11), 366A–366A.
  
• Campth-1H for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL): The Stanford University experience. Nguyen, D. D., Cao, T. M., Dugan, K., Starcher, S. A., Fechter, R. L., & Coutre, S. E. (2001). Campth-1H for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL): The Stanford University experience. BLOOD, 98(11), 291B–291B.
  
• Molecular progenitor profiling in human myeloproliferative disorders. Jamieson, C. H. M., Gotlib, J., Chao, M., Mariappan, M. R., LayRaj, M., Jones, C., … Weissman, I. L. (2005). Molecular progenitor profiling in human myeloproliferative disorders. BLOOD, 106(11), 38A–39A.
  
• A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS Garcia-Manero, G., Luger, S., Venugopal, P., Maness, L., Wetzler, M., Coutre, S., … Kantarjian, H. (2009). A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• Prognostic progenitor profiling in chronic myelomonocytic leukemia Jamieson, C. H. M., Li, K., Gotlib, J., Coutre, S. E., Lagasse, E., & Weissman, I. L. (2005). Prognostic progenitor profiling in chronic myelomonocytic leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(2), 59–59.
  
• Chronic myelomonocytic leukemia: Demonstration of failed monocyte apoptosis as a pathogenic event in mouse and man Lagasse, E., Coutre, S. E., & Weissman, I. L. (1998). Chronic myelomonocytic leukemia: Demonstration of failed monocyte apoptosis as a pathogenic event in mouse and man. EXPERIMENTAL HEMATOLOGY, 26(8), 787–787.
  
• Predictive progenitor profiling in chronic myelomonocytic leukemia. Jamieson, C., Gotlib, J., Coutre, S., Li, K., & Weissman, I. (2004). Predictive progenitor profiling in chronic myelomonocytic leukemia. BLOOD, 104(11), 268B–268B.
  
• Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., … Zehnder, J. (2009). Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Sharman, J., de Vos, S., Leonard, J. P., Furman, R. R., Coutre, S. E., Flinn, I. W., … Miller, L. L. (2011). A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). BLOOD, 118(21), 779–780.
  
• Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study Fowler, N. H., de Vos, S., Schreeder, M. T., Leonard, J. P., Flinn, I. W., Coutre, S., … Godfrey, W. R. (2012). Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study. BLOOD, 120(21).
  
• Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., … O'Brien, S. (2013). Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 369(1), 32–42.
  
• Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., … Alizadeh, A. A. (2009). Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS). BLOOD, 114(22), 646–47.
  
• Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., … Naganuma, M. (2013). Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(9), 1047–55.
  
• Acute myeloid leukemia, version 2.2013. O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., … Naganuma, M. (2013). Acute myeloid leukemia, version 2.2013. Journal of the National Comprehensive Cancer Network , 11(9), 1047–1055.
  
• Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., … Byrd, J. C. (2014). Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. LANCET ONCOLOGY, 15(1), 48–58.
  
• A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia Nand, S., Othus, M., Godwin, J. E., Willman, C. L., Norwood, T. H., Howard, D. S., … Appelbaum, F. R. (2013). A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. BLOOD, 122(20), 3432–3439.
  
• Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy Coutre, S. E., Othus, M., Powell, B., Willman, C. L., Stock, W., Paietta, E., … Appelbaum, F. R. (2014). Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. BRITISH JOURNAL OF HAEMATOLOGY, 165(4), 497–503.
  
• Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., … O'Brien, S. M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 370(11), 997–1007.
  
• SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia Advani, A. S., McDonough, S., Coutre, S., Wood, B., Radich, J., Mims, M., … Appelbaum, F. R. (2014). SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 165(4), 504–509.
  
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., … Hillmen, P. (2014). Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. New England Journal of Medicine, 371(3), 213–223.
  
• Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Coutre, S. E., Othus, M., Powell, B., Willman, C. L., Stock, W., Paietta, E., … Appelbaum, F. R. (2014). Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British Journal of Haematology, 165(4), 497–503.
  
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., … O'Brien, S. M. (2014). Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 370(11), 997–1007.
  
• SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Advani, A. S., McDonough, S., Coutre, S., Wood, B., Radich, J., Mims, M., … Appelbaum, F. R. (2014). SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology, 165(4), 504–509.
  
• A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Nand, S., Othus, M., Godwin, J. E., Willman, C. L., Norwood, T. H., Howard, D. S., … Appelbaum, F. R. (2013). A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood, 122(20), 3432–3439.
  
• Arsenic Trioxide Consolidation Improves Event-free and Overall Survival among Patients with Newly Diagnosed Acute Promyelocytic Leukemia: North American Intergroup Protocol C9710. Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., Stone, R. M., … Larson, R. A. (2008). Arsenic Trioxide Consolidation Improves Event-free and Overall Survival among Patients with Newly Diagnosed Acute Promyelocytic Leukemia: North American Intergroup Protocol C9710. ANNALS OF HEMATOLOGY, 87, S77–S78.
  
• Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma Flinn, I. W., Kahl, B. S., Leonard, J. P., Furman, R. R., Brown, J. R., Byrd, J. C., … Spurgeon, S. E. (2014). Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. BLOOD, 123(22), 3406–13.
  
• A phase 1 study of the PI3K delta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., … Wagner-Johnston, N. D. (2014). A phase 1 study of the PI3K delta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). BLOOD, 123(22), 3398–3405.
  
• Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 delta, for relapsed/refractory chronic lymphocytic leukemia Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., … Furman, R. R. (2014). Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 delta, for relapsed/refractory chronic lymphocytic leukemia. BLOOD, 123(22), 3390–97.
  
• Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45.
  
• A Pediatric Case of T-Cell Prolymphocytic Leukemia Mitton, B., Coutre, S., Willert, J., Schlis, K., Porteus, M., Kharbanda, S., & Agarwal-Hashmi, R. (2015). A Pediatric Case of T-Cell Prolymphocytic Leukemia. PEDIATRIC BLOOD & CANCER, 62(6), 1061–62.
  
• PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma Richardson, P. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., … Lonial, S. (2013). PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. BLOOD, 122(14), 2331–2337.
  
• Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Liedtke, M., Dunn, T., Dinner, S., Coutré, S. E., Berube, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research, 38(12), 1441–45.
  
• Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., … O'Brien, S. (2015). Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. BLOOD, 125(16), 2497–2506.
  
• Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–15.
  
• Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides. Louie, C. Y., DiMaio, M. A., Matsukuma, K. E., Coutre, S. E., Berry, G. J., & Longacre, T. A. (2015). Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides. American Journal of Surgical Pathology, 39(12), 1653–60.
  
• Management of adverse events associated with idelalisib treatment: expert panel opinion Coutre, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., … Zelenetz, A. D. (2015). Management of adverse events associated with idelalisib treatment: expert panel opinion. LEUKEMIA & LYMPHOMA, 56(10), 2779–86.
  
• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., … Kipps, T. J. (2015). Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 373(25), 2425–37.
  
• Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide Sanford, D., Lo-Coco, F., Sanz, M. A., Di Bona, E., Coutre, S., Altman, J. K., … Cortes, J. E. (2015). Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. BRITISH JOURNAL OF HAEMATOLOGY, 171(4), 471–77.
  
• Acute Lymphoblastic Leukemia, Version 2.2015 Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Barta, S. K., Borate, U., … Smith, C. (2015). Acute Lymphoblastic Leukemia, Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(10), 1240–79.
  
• A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia O'Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., … Coutre, S. E. (2015). A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. BLOOD, 126(25), 2686–94.
  
• A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59.
  
• Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. LEUKEMIA & LYMPHOMA, 57(3), 609–15.
  
• Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., … Wierda, W. G. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. LANCET ONCOLOGY, 17(6), 768–78.
  
• Discussion: Managing Risk When Using Idelalisib. Coutre, S. E., Burger, J. A., & Pagel, J. M. (2016). Discussion: Managing Risk When Using Idelalisib. Clinical Advances in Hematology & Oncology : H&O, 14(5), 13-?
  
• Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. (2016). British Journal of Haematology.
  
• Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., Attar, E., … Gregory, K. M. (2012). Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 984–1021.
  
• Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., … Miklos, D. B. (2016). Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood.
  
• Evolving Frontline Treatment in Chronic Lymphocytic Leukemia. Coutre, S. E. (2016). Evolving Frontline Treatment in Chronic Lymphocytic Leukemia. Clinical Advances in Hematology & Oncology : H&O, 14(5), 5–6.
  
• Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia Baljevic, M., Dumitriu, B., Lee, J.-W., Paietta, E. M., Wiernik, P. H., Racevskis, J., … Tallman, M. S. (2016). Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. ACTA HAEMATOLOGICA, 136(4), 210–18.
  
• Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., … Stilgenbauer, S. (2016). Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. LANCET ONCOLOGY, 17(10), 1409–18.
  
• Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Coutré, S. E., Furman, R. R., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., … O'Brien, S. (2017). Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(5), 1149–55.
  
• Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Mantha, S., Goldman, D. A., Devlin, S. M., Lee, J.-W., Zannino, D., Collins, M., … Tallman, M. S. (2017). Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood.
  
• Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL Barr, P. M., Brown, J. R., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., … Byrd, J. C. (2017). Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. BLOOD, 129(19), 2612–15.
  
• Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. Jones, J. A., Hillmen, P., Coutre, S., Tam, C., Furman, R. R., Barr, P. M., … O'Brien, S. M. (2017). Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. British Journal of Haematology.
  
• study in patients with previously treated CLL/SLL. Brown, J. R., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S. E., … Byrd, J. C. (2017). study in patients with previously treated CLL/SLL. Leukemia.
  
• Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial Jones, J. A., Robak, T., Brown, J. R., Awan, F. T., Badoux, X., Coutre, S., … Owen, C. (2017). Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. LANCET HAEMATOLOGY, 4(3), E114–E126.
  
• Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia.
  
• A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology.
  
• Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies Kipps, T. J., Mahler, M., Fraser, G., Coutre, S., Brown, J., Barrientos, J., … Hillmen, P. (2017). Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies. LEUKEMIA & LYMPHOMA, 58, 10–12.
  
• Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Stilgenbauer, S., Eichhorst, B., Schetelig, J., Hillmen, P., Seymour, J. F., Coutre, S., … Wierda, W. G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017766840.
  
• Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Coutre, S., Tedeschi, A., Robak, T., Barr, P. M., Owen, C., Bairey, O., … Kipps, T. J. (2018). Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 103(6), e249–e251.
  
• Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience O'Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., … Byrd, J. C. (2018). Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. BLOOD, 131(17), 1910–19.
  
• Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., … Pastan, I. (2018). Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. BLOOD, 131(21), 2331–34.
  
• Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML Swords, R. T., Coutre, S., Maris, M. B., Zeidner, J. F., Foran, J. M., Cruz, J., … Savona, M. R. (2018). Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. BLOOD, 131(13), 1415–24.
  
• Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., … Byrd, J. C. (2018). Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. LANCET ONCOLOGY, 19(1), 65–75.
  
• Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial Chyla, B., Stilgenbauer, S., Eichhorst, B., Schetelig, J., Munir, T., Hillmen, P., … Hallek, M. (2017). Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. LEUKEMIA & LYMPHOMA, 58, 234–35.
  
• Older Patients (pts) With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Treated With Ibrutinib (ibr): Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in RESONATE-2 Owen, C., Tedeschi, A., Coutre, S., Dean, J. P., Burger, J. A., & Kipps, T. J. (2018). Older Patients (pts) With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Treated With Ibrutinib (ibr): Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in RESONATE-2. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 66, S127.
  
• Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia A Pooled Analysis of 2 Clinical Trials O'Brien, S. M., Jaglowski, S., Byrd, J. C., Bannerji, R., Blum, K. A., Fox, C. P., … Coutre, S. E. (2018). Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia A Pooled Analysis of 2 Clinical Trials. JAMA ONCOLOGY, 4(5), 712–16.
  
• Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy Coutre, S., Choi, M., Furman, R. R., Eradat, H., Heffner, L., Jones, J. A., … Davids, M. S. (2018). Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. BLOOD, 131(15), 1704–11.
  
• Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies Statler, A., Othus, M., Erba, H. P., Chauncey, T. R., Radich, J. P., Coutre, S., … Sekeres, M. A. (2018). Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. BLOOD, 131(25), 2782–88.
  
• Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p Barnes, J., Divi, V., Begaye, A., Wong, R., Coutre, S., Owens, D. K., & Goldhaber-Fiebert, J. D. (2018). Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. BLOOD ADVANCES, 2(15), 1946–56.
  
• Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials Jones, J., Mato, A., Coutre, S., Byrd, J. C., Furman, R. R., Hillmen, P., … O'Brien, S. M. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials. BRITISH JOURNAL OF HAEMATOLOGY, 182(4), 504–12.
  
• Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 Barr, P. M., Robak, T., Owen, C., Tedeschi, A., Bairey, O., Bartlett, N. L., … Ghia, P. (2018). Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. HAEMATOLOGICA, 103(9), 1502–10.
  
• High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial Schiller, G. J., Damon, L. E., Coutre, S. E., Hsu, P., Bhat, G., & Douer, D. (2018). High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY.
  
• Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a 4-year follow-up from the RESONATE-2 study Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., … Kipps, T. P. (2018). Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a 4-year follow-up from the RESONATE-2 study. ONCOLOGY RESEARCH AND TREATMENT, 41, 29.
  
• Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies Robak, T., Burger, J. A., Tedeschi, A., Barr, P. M., Owen, C., Bairey, O., … Ghia, P. (2018). Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. AMERICAN JOURNAL OF HEMATOLOGY, 93(11), 1402–10.
  
• Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma O'Brien, S., Hillmen, P., Coutre, S., Barr, P. M., Fraser, G., Tedeschi, A., … Valentino, R. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(10), 648-+.
  
• Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis Yeung, C. C. S., Hockenbery, D. M., Westerhoff, M., Coutre, S. E., Sedlak, R. H., Dubowy, R. L., … Bosch, F. (2018). Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. FUTURE ONCOLOGY, 14(22), 2265–77.
  
• Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., … Byrd, J. C. (2018). Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. The New England Journal of Medicine.
  
• Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. Brown, J. R., Moslehi, J., Ewer, M. S., O'Brien, S. M., Ghia, P., Cymbalista, F., … Burger, J. A. (2018). Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. British Journal of Haematology.
  
• Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Barrientos, J. C., O'Brien, S., Brown, J. R., Kay, N. E., Reddy, N. M., Coutre, S., … Hillmen, P. (2018). Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18(12), 803-+.
  
• NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., … Sundar, H. (2019). NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. Journal of the National Comprehensive Cancer Network : JNCCN, 17(1), 12–20.
  
• Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Wierda, W. G., Byrd, J. C., O'Brien, S., Coutre, S., Barr, P. M., Furman, R. R., … Tam, C. S. (2019). Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. British Journal of Haematology.
  
• Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis. O'Brien, S. M., Byrd, J. C., Hillmen, P., Coutre, S., Brown, J. R., Barr, P. M., … Burger, J. A. (2019). Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis. American Journal of Hematology.
  
• Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., … O'Brien, S. M. (2018). Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. BLOOD, 132.
  
• Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., … Byrd, J. C. (2018). Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. BLOOD, 132.
  
• Long-term follow-up of the RESONATE phase 3 trial of ibrutinib versus ofatumumab. Byrd, J. C., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., … Brown, J. R. (2019). Long-term follow-up of the RESONATE phase 3 trial of ibrutinib versus ofatumumab. Blood.
  
• LONG-TERM FOLLOW-UP OF SINGLE-AGENT IBRUTINIB IN FIRST-LINE AND RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA Reid, M., Settlemire, J., Liu, E., Amaya-Chanaga, C., Coutre, S., & Byrd, J. (2019). LONG-TERM FOLLOW-UP OF SINGLE-AGENT IBRUTINIB IN FIRST-LINE AND RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA. ONCOLOGY NURSING FORUM, 46(2).
  
• Durability of Response to Venetoclax (VEN) in Patients with CLL Relapsed/Refractory to Ibrutinib and/or Idelalisib Byrd, J., Wierda, W., Davids, M., Choi, M., Furman, R., Mato, A., … Coutre, S. (2019). Durability of Response to Venetoclax (VEN) in Patients with CLL Relapsed/Refractory to Ibrutinib and/or Idelalisib. BRITISH JOURNAL OF HAEMATOLOGY, 185, 83–84.
  
• Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., … Stilgenbauer, S. (2019). Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801460.
  
• Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Brown, J. R., Moslehi, J., O'Brien, S., Ghia, P., Hillmen, P., Cymbalista, F., … Burger, J. A. (2017). Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 102(10), 1796–1805.
  
• Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Mato, A. R., Wierda, W. G., Davids, M. S., Cheson, B. D., Coutre, S. E., Choi, M., … Byrd, J. C. (2019). Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica.
  
• Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Shustik, C., Bence-Bruckler, I., Delage, R., Owen, C. J., Toze, C. L., & Coutre, S. (2017). Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Annals of Hematology, 96(7), 1185–96.
  
• A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. O'Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., … Coutre, S. E. (2015). A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood, 126(25), 2686–94.
  
• Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Roberts, A. W., Ma, S., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B., … Seymour, J. F. (2019). Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood.
  
• Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab Byrd, J. C., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., … Brown, J. R. (2019). Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. BLOOD, 133(19), 2031–42.
  
• Acute Lymphoblastic Leukemia, Version 1.2019 Featured Updates to the NCCN Guidelines Brown, P. A., Wieduwilt, M., Logan, A., DeAngelo, D. J., Wang, E. S., Fathi, A., … Shah, B. (2019). Acute Lymphoblastic Leukemia, Version 1.2019 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(5), 414–23.
  
• Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis O'Brien, S. M., Byrd, J. C., Hillmen, P., Coutre, S., Brown, J. R., Barr, P. M., … Burger, J. A. (2019). Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. AMERICAN JOURNAL OF HEMATOLOGY, 94(5), 554–62.
  
• Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Coutre, S. E., Byrd, J. C., Hillmen, P., Barrientos, J. C., Barr, P. M., Devereux, S., … O'Brien, S. M. (2019). Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Advances, 3(12), 1799–1807.
  
• Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D., … Ogba, N. (2019). Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 17(6), 721–49.
  
• A one-two punch with VO KOs CLL. Coutre, S. (2019). A one-two punch with VO KOs CLL. Blood, 133(26), 2737–38.
  
• Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia Wierda, W. G., Byrd, J. C., O'Brien, S., Coutre, S., Barr, P. M., Furman, R. R., … Tam, C. S. (2019). Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 186(1), 184–88.
  
• Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables Roberts, A. W., Ma, S., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B., … Seymour, J. F. (2019). Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. BLOOD, 134(2), 111–22.
  
• Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O'Brien, S., Barrientos, J., … Tallman, M. (2019). Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. The New England Journal of Medicine, 381(5), 432–43.
  
• Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Kipps, T. J., Fraser, G., Coutre, S. E., Brown, J. R., Barrientos, J. C., Barr, P. M., … Hallek, M. (2019). Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma & Leukemia.
  
• Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Munir, T., Brown, J. R., O'Brien, S., Barrientos, J. C., Barr, P. M., Reddy, N. M., … Woyach, J. A. (2019). Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology.
  
• Pooled Safety Summary for Patients Treated with the CD22-Directed Cytotoxin Moxetumomab Pasudotox-tdfk Kreitman, R., Coutre, S., Elesinmogun, C., Kuptsova-Clarkson, N., Li, X., Pastan, I., & Gladstone, D. (2019). Pooled Safety Summary for Patients Treated with the CD22-Directed Cytotoxin Moxetumomab Pasudotox-tdfk. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19, S275.
  
• Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia Burger, J., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., … Kipps, T. J. (2019). Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19, S274.
  
• ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (RR) chronic lymph ocytic leukemia (CLL). Flinn, I., Marris, M., Wierda, W. G., Coutre, S., Pagel, J. M., Byrd, J. C., … Brown, J. R. (2019). ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (RR) chronic lymph ocytic leukemia (CLL). JOURNAL OF CLINICAL ONCOLOGY, 37(15).
  
• Pooled safety summary for patients treated with the CD22-directed cytotoxi n moxetumomab pasudotox-tdfk. Kreitman, R. J., Coutre, S., Elesinmogun, C., Kuptsova-Clarkson, N., Li, X., Pastan, I., & Gladstone, D. E. (2019). Pooled safety summary for patients treated with the CD22-directed cytotoxi n moxetumomab pasudotox-tdfk. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
  
• Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. Barr, P. M., Munir, T., Brown, J. R., O'Brien, S. M., Barrientos, J. C., Reddy, N. M., … Woyach, J. A. (2019). Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
  
• Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., … Kipps, T. J. (2019). Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia.
  
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. Shanafelt, T. D., Wang, V., Kay, N. E., Hanson, C. A., O'Brien, S. M., Barrientos, J. C., … Tallman, M. S. (2019). Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. Blood, 134(Supplement_1), 33.
  
• ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Sharman, J. P., Banerji, V., Fogliatto, L. M., Herishanu, Y., Munir, T., Walewska, R., … Byrd, J. C. (2019). ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood, 134(Supplement_1), 31.
  
• Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Coutre, S. E., Flinn, I. W., de Vos, S., Barrientos, J. C., Schreeder, M. T., Wagner-Johnson, N. D., … Furman, R. R. (2018). Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. HemaSphere, 2(3), e39.
  
• Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy Mato, A. R., Wierda, W. G., Davids, M. S., Cheson, B. D., Coutre, S. E., Choi, M., … Byrd, J. C. (2019). Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. HAEMATOLOGICA, 104(11), 2258–64.
  
• Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial. Ghia, P., Coutre, S. E., Cheson, B. D., Barrientos, J. C., Hillmen, P., Pettitt, A. R., … Furman, R. R. (2020). Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial. Haematologica.
  
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020 Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., … Sundar, H. (2020). Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 18(2), 185–217.
  
• Elevate Tn Phase 3 Study of Acalabrutinib Plus Obinutuzumab or Acalabrutinib Monotherapy vs Chlorambucil Plus Obinutuzumab (ClbO) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Martens, U., Sharman, J., Banerji, V., Fogliatto, L. M., Herishanus, Y., Munir, T., … Byrd, J. (2020). Elevate Tn Phase 3 Study of Acalabrutinib Plus Obinutuzumab or Acalabrutinib Monotherapy vs Chlorambucil Plus Obinutuzumab (ClbO) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL). ONCOLOGY RESEARCH AND TREATMENT, 43, 127.
  
• Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study. Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J., Blum, K. A., … O'Brien, S. (2020). Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
  
• Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., … Byrd, J. C. (2020). Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (London, England), 395(10232), 1278–91.
  
• A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Lancet, J. E., Moseley, A. B., Coutre, S. E., DeAngelo, D. J., Othus, M., Tallman, M. S., … Appelbaum, F. R. (2020). A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Advances, 4(8), 1683–89.
  
• Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., … Byrd, J. C. (2020). Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. LANCET, 395(10232), 1278–91.
  
• ELEVATE-TN: a phase 3, multicentre, open-label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Clb) in patients (pts) with treatment-naive chronic lymphocytic leukaemia (TN-CLL) Munir, T., Sharman, J., Banerji, V., Fogliatto, L. M., Herishanu, Y., Walewska, R., … Byrd, J. C. (2020). ELEVATE-TN: a phase 3, multicentre, open-label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Clb) in patients (pts) with treatment-naive chronic lymphocytic leukaemia (TN-CLL). BRITISH JOURNAL OF HAEMATOLOGY, 189, 26–28.
  
• Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age: results with 5 years of follow-up for the RESONATE-2 study Tedeschi, A., Burger, J. A., Barr, P., Robak, T., Owen, C., Ghia, P., … Kipps, T. J. (2020). Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age: results with 5 years of follow-up for the RESONATE-2 study. LEUKEMIA & LYMPHOMA, 61, 38–40.
  
• Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. Marukian, N. V., Lin, J. Q., Colevas, A. D., Coutre, S., & Chang, A. L. (2020). Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma. JAAD Case Reports, 6(9), 819–21.
  
• FIVE YEARS OF FOLLOW-UP FROM THE PHASE 3 RESONATE-2 STUDY AND NURSING EXPERIENCE WITH PATIENTS RECEIVING FIRST-LINE IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA Greenberg, E. M., Settlemire, M., Lal, I., Amaya-Chanaga, C., Coutre, S., & Burger, J. A. (2020). FIVE YEARS OF FOLLOW-UP FROM THE PHASE 3 RESONATE-2 STUDY AND NURSING EXPERIENCE WITH PATIENTS RECEIVING FIRST-LINE IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA. ONCOLOGY NURSING FORUM, 47(2).
  
• Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., … Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1–6.